Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
New digital health player HealthHero launches with Fernarzt buyThere’s a new kid on the block in digital health – called HealthHero – with aspirations to become Share XNew digital health player HealthHero launches with Fernarzt buyhttps://pharmaphorum.com/news/new-digital-health-player-healthhero-launches-with-fernarzt-buy/
Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in EuropeRoche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK Share XRoche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europehttps://pharmaphorum.com/news/roches-tumour-agnostic-therapy-approved-in-europe/
The acceleration of pharma’s digital transformationFrom this summer’s vantage point 2019 seems like it was at least a decade ago, such is the Share XThe acceleration of pharma’s digital transformationhttps://pharmaphorum.com/digital/the-acceleration-of-pharmas-digital-transformation/
Novartis, company culture and COVID-19: the pharmaphorum podcastNovartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face Share XNovartis, company culture and COVID-19: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/novartis-company-culture-covid-19/
Next wave: how pharma analytics can be improved with new technologiesPharmaceutical companies have always had access to a steady stream of data to look at what has happened Share XNext wave: how pharma analytics can be improved with new technologieshttps://pharmaphorum.com/views-and-analysis/next-wave-how-pharma-analytics-can-be-improved-with-new-technologies/
GSK’s John Fleming on rethinking oncology from the ground upWhat if we could look at cancer treatment from a completely fresh perspective? This is the philosophy GSK’s Share XGSK’s John Fleming on rethinking oncology from the ground uphttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/gsks-john-fleming-on-rethinking-oncology-from-the-ground-up/
Commercialising innovative new medicinesAs pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination Share XCommercialising innovative new medicineshttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/commercialising-innovative-new-medicines/
How to increase haematologists’ and oncologists’ confidence with new treatmentsA new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments Share XHow to increase haematologists’ and oncologists’ confidence with new treatmentshttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/how-to-increase-haematologists-and-oncologists-confidence-with-new-treatments/
Clinical decision-making insights for haem/oncs Share XClinical decision-making insights for haem/oncshttps://pharmaphorum.com/oncology/clinical-decision-making-insights-haem-oncs/
How to win with a multichannel approach in pharma Share XHow to win with a multichannel approach in pharmahttps://pharmaphorum.com/digital/multichannel-approach-pharma-viseven/
Accelerating pharma’s digital IQ as customer engagement evolves Share XAccelerating pharma’s digital IQ as customer engagement evolveshttps://pharmaphorum.com/digital/veeva-customer-engagement-webinar/
Customer experience in healthcare – a strategic priority for pharmaCustomer experience (CX) is widely, and rightly, acknowledged to be one of the pharmaceutical industry’s top strategic priorities. Share XCustomer experience in healthcare – a strategic priority for pharmahttps://pharmaphorum.com/whitepapers/customer-experience-strategy-healthcare-pharma/
Preparing for the next decade of innovation in immuno-oncologyImmuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic Share XPreparing for the next decade of innovation in immuno-oncologyhttps://pharmaphorum.com/oncology/immuno-oncology-clinicial-trial-market-access/
Pharma’s roadmap for successful online engagement with HCPsHealthcare professionals (HCPs) rate websites as their number one source for clinical practice information and mobile technology has Share XPharma’s roadmap for successful online engagement with HCPshttps://pharmaphorum.com/sales-marketing/pharma-roadmap-online-hcp-engagement/
Novartis, company culture and COVID-19: the pharmaphorum podcast Share XNovartis, company culture and COVID-19: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/novartis-company-culture-covid-19/
Investing in innovation – new digital approaches for a new decade Share XInvesting in innovation – new digital approaches for a new decadehttps://pharmaphorum.com/views-analysis-digital/investing-in-innovation-new-digital-approaches-for-a-new-decade/
China’s COVID-19 experience – the Health Heroes podcast Share XChina’s COVID-19 experience – the Health Heroes podcasthttps://pharmaphorum.com/podcast/china-experience-covid-19-pandemic/
New speaker session with Kiniksa Pharmaceuticals at Pre-filled Syringes East Coast 2020 Share XNew speaker session with Kiniksa Pharmaceuticals at Pre-filled Syringes East Coast 2020https://pharmaphorum.com/partner-content/new-speaker-session-with-kiniksa-pharmaceuticals-at-pre-filled-syringes-east-coast-2020/
Managing and Tracking Cross-functional KOL Collaborations Share XManaging and Tracking Cross-functional KOL Collaborationshttps://pharmaphorum.com/partner-content/managing-and-tracking-cross-functional-kol-collaborations/
Understanding COVID-19 and varying responses across the globe Share XUnderstanding COVID-19 and varying responses across the globehttps://pharmaphorum.com/partner-content/understanding-covid-19-and-varying-responses-across-the-globe/
J+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTER Share XJ+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERhttps://pharmaphorum.com/partner-content/jd-forecasting-makes-the-pharma-forecasting-experience-even-better/
Prescient Announces Recent Appointments to the Senior Advisory Team Share XPrescient Announces Recent Appointments to the Senior Advisory Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-the-senior-advisory-team/
Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team Share XPrescient Intelligence & Insight Announces Recent Appointments to the Senior Teamhttps://pharmaphorum.com/partner-content/prescient-intelligence-insight-announces-recent-appointments-to-the-senior-team-2/
